Phase 1 trial investigating safety of RP-6503 for the treatment of airway disorders
Latest Information Update: 05 Jul 2013
Price :
$35 *
At a glance
- Drugs RP 6503 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 05 Jul 2013 New trial record